Addex Therapeutics Ltd
SIX:ADXN

Watchlist Manager
Addex Therapeutics Ltd Logo
Addex Therapeutics Ltd
SIX:ADXN
Watchlist
Price: 0.0544 CHF Market Closed
Market Cap: CHf10m

Operating Margin

-375.4%
Current
Improving
by 288.4%
vs 3-y average of -663.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-375.4%
=
Operating Income
CHf-2.1m
/
Revenue
CHf555.2k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-375.4%
=
Operating Income
CHf-2.1m
/
Revenue
CHf555.2k

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Addex Therapeutics Ltd
SIX:ADXN
10m CHF
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 96% of companies in Switzerland
Percentile
4th
Based on 1 083 companies
4th percentile
-375.4%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Addex Therapeutics Ltd
Glance View

Market Cap
10m CHF
Industry
Biotechnology

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 28 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

ADXN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-375.4%
=
Operating Income
CHf-2.1m
/
Revenue
CHf555.2k
What is Addex Therapeutics Ltd's current Operating Margin?

The current Operating Margin for Addex Therapeutics Ltd is -375.4%, which is above its 3-year median of -663.9%.

How has Operating Margin changed over time?

Over the last 3 years, Addex Therapeutics Ltd’s Operating Margin has increased from -1 335.5% to -375.4%. During this period, it reached a low of -1 420.1% on Dec 31, 2022 and a high of -138.7% on Dec 31, 2023.

Back to Top